跳至主要内容

Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52674#.VKC5YcCAM4

Background: Dose-modified (dm) CODOX-M/IVAC is commonly used for Burkitt lymphoma (BL) and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and BL (BCL-U; previously Burkitt-like lymphoma-BLL). Methods: We evaluated the clinical characteristics, outcomes and prognostic markers in patients treated with dmCODOX-M/IVAC+/- rituximab (R) at a single academic center. Results: 31 patients with BL (n = 21) or BCL-U (n = 10) were included. The median age was 45, and 90% were high risk. The 2-year overall survival (OS) and progression-free survival (PFS) were 69% and 62%, respectively, with no differences between BL and BCL-U. By multivariable analysis, rituximab use was significantly associated with improved OS (Hazard Ratio 0.15; 95% CI 0.04 - 0.56) while elevated LDH (Hazard Ratio 2.84, 95% CI 1.52 - 5.29) and rituximab use (Hazard Ratio 0.054, 95% CI 0.01 - 0.32) predicted PFS. Conclusion: DmCODOX-M/IVAC+/- R chemotherapy provides equivalent survival for both BL and BCL-U patients. The addition of rituximab improves overall and progression free survival and is recommended.
Cite this paper
Prica, A. , Pratzer, A. , Cheung, M. , Thompson, K. , Piliotis, E. , Berinstein, N. , Imrie, K. , Pradhan, R. , Vyas, A. , Ghorab, Z. , Good, D. , Zhang, L. and Buckstein, R. (2015) Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature. Journal of Cancer Therapy, 6, 1-11. doi: 10.4236/jct.2015.61001. 
 

[1] Swerdlo, S., Campo, E., Harris, N., et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
[2] Haralambieva, E., Boerma, E.J., Van Imhoff, G.W., et al. (2005) Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas with Morphologic Features of Burkitt Lymphoma. The American Journal of Surgical Pathology, 29, 1086-1094.
[3] Magrath, I., Adde, M., Shad, A., et al. (1996) Adults and Children with Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated with the Same Chemotherapy Regimen. Journal of Clinical Oncology, 14, 925-934.
[4] Magrath, I.T., Janus, C. and Sariban, E. (1984) Therapy of Localized Non-Hodgkin’s Lymphoma in Children. Journal of Clinical Oncology, 2, 140-141.
[5] Mead, G.M., Barrans, S.L., Qian, W., et al. (2008) A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients with Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial). Blood, 112, 2248-2260.
http://dx.doi.org/10.1182/blood-2008-03-145128
[6] Lacasce, A., Howard, O., Lib, S., et al. (2004) Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity. Leukemia & Lymphoma, 45, 761-767. http://dx.doi.org/10.1080/1042819031000141301
[7] Mead, G.M., Sydes, M.R., Walewski, J., et al. (2002) An International Evaluation of CODOX-M and CODOX-M Alternating with IVAC in Adult Burkitt’s Lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264-1274. http://dx.doi.org/10.1093/annonc/mdf253
[8] Barnes, J.A., Lacasce, A.S., Feng, Y., et al. (2011) Evaluation of the Addition of Rituximab to CODOX-M/IVAC for Burkitt’s Lymphoma: A Retrospective Analysis. Annals of Oncology, 22, 1859-1864. http://dx.doi.org/10.1093/annonc/mdq677
[9] Maruyama, D., Watanabe, T., Maeshima, A.M., et al. (2010) Modified Cyclophosphamide, Vincristine, Doxorubicin, and Methotrexate (CODOX-M)/Ifosfamide, Etoposide, and Cytarabine (IVAC) Therapy with or without Rituximab in Japanese Adult Patients with Burkitt Lymphoma (BL) and B Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B Cell Lymphoma and BL. International Journal of Hematology, 92, 732-743. http://dx.doi.org/10.1007/s12185-010-0728-0
[10] Mohamedbhai, S.G., Sibson, K., Marafioti, T., et al. (2011) Rituximab in Combination with CODOX-M/IVAC: A Retrospective Analysis of 23 Cases of Non-HIV Related B-Cell Non-Hodgkin Lymphoma with Proliferation Index >95%. British Journal of Haematology, 152, 175-181.
http://dx.doi.org/10.1111/j.1365-2141.2010.08447.x
[11] Corazzelli, G., Frigeri, F., Russo, F., Frairia, C., Arcamone, M., Esposito, G., et al. (2012) RD-CODOX-M/IVAC with Rituximab and Intrathecal Liposomal Cytarabine in Adult Burkitt Lymphoma and “Unclassifiable” Highly Aggressive B-Cell Lymphoma. British Journal of Haematology, 156, 234-244.
http://dx.doi.org/10.1111/j.1365-2141.2011.08947.x
[12] Jaffe, E., Harris, N.L., Stein, H. and Vardiman, J., Eds. (2001) Tumours of Haematopoietic and Lymphoid Tumours. AIARC Press, Lyon, 181-184.
[13] Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., et al. (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 17, 1244.
[14] Bernstein, J.I., Coleman, C.N., Strickler, J.G., Dorfman, R.F. and Rosenberg, S.A. (1986) Combined Modality Therapy for Adults with Small Noncleaved Cell Lymphoma (Burkitt’s and Non-Burkitt’s Types). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 4, 847-858.
[15] Abramson, J.S., Barnes, J.A., Toomey, C.E., et al. (2008) Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and HIV-Positive Burkitt Lymphoma. ASH Annual Meeting Abstracts, 112, 3595.
[16] Blum, K.A., Lozanski, G. and Byrd, J.C. (2004) Adult Burkitt Leukemia and Lymphoma. Blood, 104, 3009-3020. http://dx.doi.org/10.1182/blood-2004-02-0405
[17] Wasterlid, T., Brown, P.N., Hagberg, O., Hagberg, H., Pedersen, L.M., D’Amore, F. and Jerkeman, M. (2013) Impact of Chemotherapy Regimen and Rituximab in Adult Burkitt Lymphoma: A Retrospective Population-Based Study from the Nordic Lymphoma Group. Annals of Oncology, 24, 1879-1886.
http://dx.doi.org/10.1093/annonc/mdt058?
[18] Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. and Abramson, J.S. (2011) Evaluation of the Addition of Rituximab to CODOX-M/IVAC for Burkitt’s Lymphoma: A Retrospective Analysis. Annals of Oncology, 22, 1859-1864. http://dx.doi.org/10.1093/annonc/mdq677
[19] Ribrag, V., Koscielny, S., Bouabdallah, K., Herbrecht, R., Iacobelli, S., Bosq, J., et al. (2012) Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR Sponsored LMBA02, NCT00180882). ASH Annual Meeting Abstracts, 120, 685.
[20] Green, T.M., Young, K.H., Visco, C., Xu-Monette, Z.Y., Orazi, A., Go, R.S., et al. (2012) Immunohisto- chemical Double-Hit Score Is a Strong Predictor of Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 30, 3460-3467. http://dx.doi.org/10.1200/JCO.2011.41.4342
[21] Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., et al. (2012) Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 30, 3452-3459. http://dx.doi.org/10.1200/JCO.2011.41.0985
[22] Pfreundschuh, M., Trümper, L., Kloess, M., Schmits, R., Feller, A.C., Rübe, C., et al. (2004) Two-Weekly or 3-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Elderly Patients with Aggressive Lymphomas: Results of the NHL-B2 Trial of the DSHNHL. Blood, 104, 634-641.
http://dx.doi.org/10.1182/blood-2003-06-2095
[23] Smeland, S., Blystad, A.K., Kval?y, S.O., Ikonomou, I.M., Delabie, J., Kvalheim, G., Hammerstr?m, J., Lauritzsen, G.F. and Holte, H. (2004) Treatment of Burkitt’s/Burkitt-Like Lymphoma in Adolescents and Adults: A 20-Year Experience from the Norwegian Radium Hospital with the Use of Three Successive Regimens. Annals of Oncology, 15, 1072-1078. http://dx.doi.org/10.1093/annonc/mdh262
[24] Perry, A.M., Crockett, D., Dave, B.J., Althof, P., Winkler, L., Smith, L.M., et al. (2013) B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma: Study of 39 Cases. British Journal of Haematology, 162, 40-49.
http://dx.doi.org/10.1111/bjh.12343                           eww141229lx
 
标签：

评论

发表评论

此博客中的热门博文

Does Immigration Promote the Investment of the Monopolistic Firm?

In the present paper, we examine the effect of increasing uncertainty of immigrants’ growth on the optimal timing of investment of a firm that has a monopolistic power over the labor market. It is revealed that when the uncertainty of immigrants’ growth is more than a threshold level, increasing uncertainty of immigrants’ growth accelerates the optimal timing of firms’ investment and enhances the economic growth, even if the uncertainty of immigrants’ growth is formulated by the geometric Brownian motion, which is in sharp contrast to the standard result that an increase in the uncertainty postpones the optimal timing. With an increase in the immigrants over the past ten years, workforces in the host countries have been growing significantly to the extent that the immigrants represent 70% of the increase in the workforce in Europe, and 47% in the United States as OECD indicates. In the present paper, we attempted to investigate the effect of increased uncertainty caused by the growi...
发表评论
阅读全文

Education Policy Implementation: A Mechanism for Enhancing Primary Education Development in Zanzibar

Education is one of the fundamental rights of individuals; therefore, the government of a country needs to develop and strengthen educational policy and quality as well as to ensure that everyone has equal access to basic education. The improvement of access and quality of education in the world is becoming as an essential factor in development, whereas the basic education (primary school), is acknowledged as a foundation of the higher educational development for every country. To fulfill this goal, governments introduce several policies and procedures; however, it requires some reforms and participation from the politician, policymakers, and other stakeholders to re-examine educational policy so that it can lead to multiplication and betterment of the reforms. Educational reforms actually focus on accountability. A positive educational development and reform is very challenging and needs more effort and strategy on how to use and utilize the resources effectively as such it can achie...
发表评论
阅读全文

Electron Spin and Proton Spin in the Hydrogen and Hydrogen-Like Atomic Systems

Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=52202#.VIj7tMnQrzE Author(s) Stanisław Olszewski * Affiliation(s) Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland . ABSTRACT The mechanical angular momentum and magnetic moment of the electron and proton spin have been calculated semiclassically with the aid of the uncertainty principle for energy and time. The spin effects of both kinds of the elementary particles can be expressed in terms of similar formulae. The quantization of the spin motion has been done on the basis of the old quantum theory. It gives a quantum number n = 1/2 as the index of the spin state acceptable for both the electron and proton ...
发表评论
阅读全文